Skip to content

A multicenter randomized controlled trial of Qingre Liangxue therapy for psoriasis blood-heat syndrome

A multicenter randomized controlled trial of Qingre Liangxue therapy for psoriasis blood-heat syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026334
Enrollment
Unknown
Registered
2019-09-30
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Sponsors

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Western diagnostic criteria and diagnostic criteria for TCM syndromes that meet psoriasis; 2. Skin lesions involve <=10% BSA (the lesions are mainly located in the trunk and / or limbs, palm / sole, face / scalp, vulva area is not included); 3. Age between 18 and 65 years old; 4. Those who voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Erythrodermic, arthritic, pustular psoriasis patients; 2. There are other active skin diseases that may affect the condition assessment; 3. Systematic treatment of research drugs, biological agents and immunosuppressive agents within 1 month; 4. Within 2 weeks, he received treatment with topical glucocorticoids, phototherapy, etc.; 5. During severe, uncontrollable local or systemic acute or chronic infections; 7. Patients with severe systemic diseases; or clinical test indicators in one of the following conditions: alanine aminotransferase or aspartate aminotransferase increased by >1.5 times the upper limit of normal; creatinine increased by 1.5 times the upper limit of normal; main indicators of blood routine ( Any one of the white blood cell count, red blood cell count, hemoglobin amount, and platelet count) is below the lower limit of normal; or other laboratory abnormalities are judged by the investigator to be unsuitable for participation in the trial; 8. Patients with a history of malignant tumors and primary or secondary immunodeficiency and hypersensitivity patients; 9. Those who have participated in other drug clinical trials within 3 months; 10. Such surgery will be required during major surgery or study within 8 weeks; 11. For women of childbearing age who have fertility, no effective contraceptive measures have been taken from the screening period until the end of the last dose; 12. Pregnant or lactating women; 13. Those who have a history of alcohol abuse, drug abuse or drug abuse; 14. Those with a history of serious mental illness or family history; 15. The investigator considered it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
PASI;

Secondary

MeasureTime frame
recurrence rate;BSA;PGA;DLQI;PRQoL;VAS;TCM symptom score;

Countries

China

Contacts

Public ContactCang Zang

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

askzhangcang@126.com+86 13693219292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026